

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Trastuzumab emtansine for treating HER2-  
positive, unresectable locally advanced or metastatic,  
breast cancer after treatment with trastuzumab and a  
taxane**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No equalities issues were raised during consultation on the draft scope or at the Scoping Workshop.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

N/A – No equalities issues identified.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes were made to the draft scope

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No

**Approved by Associate Director (name):** ...Janet Robertson.....

**Date:** 3 October 2013